Mark Hahn - Feb 1, 2022 Form 4 Insider Report for Verona Pharma plc (VRNA)

Role
Chief Financial Officer
Signature
/s/ Claire Poll, Attorney-in-fact for Mark Hahn
Stock symbol
VRNA
Transactions as of
Feb 1, 2022
Transactions value $
-$131,673
Form type
4
Date filed
2/3/2022, 04:54 PM
Previous filing
Nov 18, 2021
Next filing
May 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRNA Ordinary Shares Award $100K +134K +0.84% $0.75* 16.1M Feb 1, 2022 Direct F1, F2
transaction VRNA Ordinary Shares Tax liability -$224K -288K -1.79% $0.78* 15.8M Feb 1, 2022 Direct F1, F3, F4
transaction VRNA Ordinary Shares Sale -$7.88K -10.4K -0.07% $0.76* 15.8M Feb 2, 2022 Direct F1, F5, F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
F2 The price reported represents the closing price of the Issuer's ADSs on the Nasdaq Stock Market LLC on January 28, 2022 divided by eight (8).
F3 Represents the number of Ordinary Shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported Restricted Share Units.
F4 The price reported represents the closing price of the Issuer's ADSs on the Nasdaq Stock Market LLC on January 31, 2022 divided by eight (8).
F5 The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported Restricted Share Units.
F6 The price reported is a weighted average price, and is based on the sale price of the ADSs divided by eight (8). The securities were sold in multiple transactions at per share prices ranging from $0.7462 to $0.7863. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 5.
F7 Consists of (i) 9,381,112 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 1,172,639 ADSs); and (ii) 6,445,048 Ordinary Shares underlying 805,631 ADSs.